A Review of the Efficacy of FDA-Approved <i>B. anthracis</i> Anti-Toxin Agents When Combined with Antibiotic or Hemodynamic Support in Infection- or Toxin-Challenged Preclinical Models
Anti-toxin agents for severe <i>B. anthracis</i> infection will only be effective if they add to the benefit of the two mainstays of septic shock management, antibiotic therapy and titrated hemodynamic support. Both of these standard therapies could negate benefits related to anti-toxin...
Main Authors: | Zoe Couse, Xizhong Cui, Yan Li, Mahtab Moayeri, Stephen Leppla, Peter Q. Eichacker |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Toxins |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6651/13/1/53 |
Similar Items
-
Anthrax immune globulin improves hemodynamics and survival during B. anthracis toxin-induced shock in canines receiving titrated fluid and vasopressor support
by: Dante A. Suffredini, et al.
Published: (2017-10-01) -
Does Bacillus anthracis Lethal Toxin Directly Depress Myocardial Function? A Review of Clinical Cases and Preclinical Studies
by: Dante A. Suffredini, et al.
Published: (2015-12-01) -
Anthrax Toxins in Context of Bacillus anthracis Spores and Spore Germination
by: Christopher K. Cote, et al.
Published: (2015-08-01) -
TaqMan Assays for Simultaneous Detection of <i>Bacillus anthracis</i> and <i>Bacillus cereus</i> biovar <i>anthracis</i>
by: Diansy Zincke, et al.
Published: (2020-12-01) -
Inhibitory Effects of a Reengineered Anthrax Toxin on Canine and Human Osteosarcoma Cells
by: Jonathan Mackowiak da Fonseca, et al.
Published: (2020-09-01)